Never miss another update

Subscribe Today!

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory reviewNature publication of promising pre-clinical results for second-generation COVID-19 vaccine candidate, CV2CoV, in study with Harvard Medical School, showing comparable immune response to a licensed mRNA vaccinePositive developments across rest of the pipeline, including pre-clinical… Read More »CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

The post CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update appeared on Stocks News Feed.

Posted in

The Markets Today